Global Alpha Emitter Market to reach USD XX billion by 2027Global Alpha Emitter Market is valued approximately at USD XX billion in 2020 and is anticipated to grow with a healthy growth rate of more than 36.7% over the forecast period 2021-2027. Alpha emitters are useful in the therapy of cancer. The properties of alpha emitters have resulted in significant differences between this discipline and other nuclear medicine specialties. Alpha particles have been widely used in medical studies due to their limited range and high LET (deposit energy per unit length of route). Ovarian cancer, pancreatic cancer, lymphoma, and melanoma are among of the malignancies that are treated using alpha emitters. The treatment method employs a variety of radionuclides, including radium, lead, and bismuth. Increased awareness of the potential advantages of targeted alpha treatment, as well as the rising number of patients with cardiac and cancer diseases, are driving market growth. Furthermore, the growth is due to an increase in the number of new diagnostic cases. According to the American Cancer Society, around 22,240 women are projected to be diagnosed with ovarian cancer in 2018, with approximately 14,070 women dying from the disease. In addition, At-211-MX35 F (ab???) showed significant effectiveness in a recent Phase I clinical trial, with therapeutic doses reaching their goals in patients with ovarian cancer. However, stringent regulatory framework and reimbursement issues may impede market growth over the forecast period of 2021-2027.

North America currently dominates the alpha emitter market, and it is projected to remain so for a few more years. The increase in cardiac and neurological chronic illnesses, which is the primary driving reason for market growth in the region. For example, 223RaCl2 (Xofigo) is the first alpha emitting radioisotope to be approved for palliative treatment of prostate cancer bone metastases by indirect physiological targeting in the United States.

Major market player included in this report are:
Alpha Tau Medical Ltd
Actinium Pharmaceuticals Inc.
IBA Radiopharma Solutions
Telix Pharmaceuticals Ltd
Fusion Pharmaceuticals
RadioMedix Inc.
Bayer AG.




The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming eight years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within each of the regions and countries involved in the study. Furthermore, the report also caters the detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, the report shall also incorporate available opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:

By Type of Radionuclide:
Astatine (At-211)
Radium (Ra-223)
Actinium (Ac-225)
Lead (Pb-212)
Bismuth (Bi-212)
Other Type of Radionuclides
By Medical Application:
Prostate Cancer
Bone Metastasis
Ovarian Cancer
Pancreatic Cancer
Endocrine Tumors
Other Medical Applications
By Region:
North America
U.S.
Canada
Europe
UK
Germany
France
Spain
Italy
ROE

Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC
Latin America
Brazil
Mexico
Rest of the World

Furthermore, years considered for the study are as follows:

Historical year - 2018, 2019
Base year - 2020
Forecast period - 2021 to 2027.

Target Audience of the Global Alpha Emitter Market in Market Study:

Key Consulting Companies & Advisors
Large, medium-sized, and small enterprises
Venture capitalists
Value-Added Resellers (VARs)
Third-party knowledge providers
Investment bankers
Investors